yellow

The objective of this prospective, open-label, randomised clinical trial, was to evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalised with COVID-19.

In this controlled, open-label trial recently published in the New England Journal of Medicine, the authors randomly assigned patients who were hospitalised with COVID-19 to receive either oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or usual care.